Seizure Disorders

Latest News

Air Pollution as a Potential Risk Factor for Epileptic Seizures

Researchers sought to examine the relationship between air pollution exposure and the occurrence of epileptic seizures.

Serious Neurologic Manifestations Associated With Worse COVID-19 Outcomes

For adults hospitalized with SARS-CoV-2 infection, encephalopathy at admission is the most common serious neurologic manifestation, all of which are associated with worse outcomes.

Prediction Tool Estimates Survival Among Patients With Status Epilepticus

Researchers sought to improve the prognostication of long-term mortality following a status epilepticus diagnosis.

Gait, Motor Function Gradually Worsened in Adults With Dravet Syndrome

In a prospective, cross-sectional study, researchers assessed gait and motor disturbances among adult patients with Dravet syndrome.

Is Breastfeeding Safe for Infants of Women With Epilepsy on Antiseizure Medication?

In a systematic review, researchers reported on the presence of antiseizure medications in the breast milk of women with epilepsy and potential infant exposure to those who were breastfed.

VNS May Cut Hospital Costs for Children With Refractory Epilepsy

Antiseizure medication (ASM) plus vagus nerve stimulation (VNS) is associated with lower annual hospital costs over time for pediatric patients with refractory epilepsy compared to ASM alone.

Long-Term Outcomes of Patients With Transient Epileptic Amnesia

Researchers sought to evaluate the long-term outcomes of transient epileptic amnesia in relation to seizure control, memory, medical comorbidities, and life expectancy.

Posttraumatic Epilepsy More Likely to Be Drug Resistant

Individuals with posttraumatic epilepsy (PTE) are more likely to have drug-resistant epilepsy (DRE), and they report lower quality of life.

Fenfluramine Shows Safety, Efficacy in Seizure Reduction in Lennox-Gastaut Syndrome

Presenting at the 2022 AAN Annual Meeting, researchers investigated the long-term efficacy of fenfluramine in patients with LGS.

Oral Perampanel Well Tolerated in Pediatric Epilepsy

Daily oral perampanel is generally well tolerated, with favorable retention rates among patients with epilepsy aged 1 to younger than 18 years.